Turbine
Hungary
- Budapest
- 20/06/2023
- Series A
- $6,004,625
Turbine was founded for a simple reason; to understand complex cancers better than existing experimental tools in order to solve unmet oncology needs.
Through a multidisciplinary team that unites computer science and molecular biology, and the world's most intricate simulation of cell behavior, we identify treatment options for the 70% of cancers that are currently unexplored.
We use our platform, the Simulated Cell™, to uncover novel biological insights across both new and known targets. This allows us to provide a fresh biological context, define responsive patient populations, and design drug combination approaches that diminish resistance.
With a process proven by clinical stage predictions and a proprietary pipeline, we continue our mission of unlocking cancer complexity to deliver next-generation precision therapeutics.
- Industry Biotechnology Research
- Website https://turbine.ai/
- LinkedIn https://www.linkedin.com/company/turbine-inc/
Vesence | $9,000,000 | (Oct 30, 2025)
Sparrow BioAcoustics | $10,000,000 | (Oct 30, 2025)
Reflectiz | $22,000,000 | (Oct 30, 2025)
Mem0 | $24,000,000 | (Oct 30, 2025)
Valthos | $30,000,000 | (Oct 30, 2025)
Mondra | $13,206,500 | (Oct 30, 2025)
hoop.dev | Undisclosed Amount | (Oct 30, 2025)
IORGANBIO | $2,000,000 | (Oct 30, 2025)
FrontlineIQ | $3,300,000 | (Oct 30, 2025)
Homecourt | $8,000,000 | (Oct 30, 2025)
VentureMed Inc. | $28,000,000 | (Oct 30, 2025)
Recess | $30,000,000 | (Oct 30, 2025)